SCHEDULE: Norwest Venture Partners Reports 5.1% Stake in Avalyn Pharma

Norwest Venture Partners XV, LP, along with affiliated entities and individuals, has reported a beneficial ownership of 5.1% of Avalyn Pharma Inc.'s common stock as of June 30, 2026.

Summary

• This filing is a Schedule 13G, indicating beneficial ownership of Avalyn Pharma Inc. common stock by Norwest Venture Partners XV, LP and related entities/individuals.
• The reporting persons collectively beneficially own 2,268,404 shares of voting common stock, representing 5.1% of the class.
• This ownership stake is directly held by NVP XV, with Genesis XV as its general partner, NVP Associates as Genesis XV's managing member, and Jeffrey Crowe and Jon E. Kossow as Co-Chief Executive Officers of NVP Associates.
• The filing states that Genesis XV, NVP Associates, Crowe, and Kossow may be deemed to share voting and investment authority over these shares.
• The total number of outstanding shares of voting common stock was 44,333,095 as of June 2, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting ownership stakes and not containing operational or financial performance updates.

Positives

• Significant investment by a venture capital firm (Norwest Venture Partners) indicates potential confidence in Avalyn Pharma's long-term prospects.
• Clear disclosure of ownership structure and beneficial interest.

Negatives

• The filing does not provide any financial performance data or operational updates for Avalyn Pharma Inc.

Risks

• The concentration of ownership by a single investment group could influence corporate decisions.
• As a Schedule 13G filing, it does not detail the investment strategy or rationale behind the ownership stake.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Avalyn Pharma Inc.'s future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and venture capital firms accumulating significant stakes in public companies. This filing indicates Norwest Venture Partners' continued interest in Avalyn Pharma, a typical move for VC firms in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which could be perceived positively or neutrally depending on market sentiment towards venture capital holdings.

Next Steps

• Continued monitoring of Avalyn Pharma Inc.'s performance and any subsequent filings by Norwest Venture Partners or other significant shareholders.

Key Dates

Keywords

Avalyn Pharma, Norwest Venture Partners, Schedule 13G, Beneficial Ownership, Venture Capital, Common Stock, Investment Management